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Dolutegravir (DTG), a second-generation integrase 
strand-transfer inhibitor (INSTI), is equivalent or supe-
rior to current non-nucleotide reverse transcriptase inhibi-
tors (NNRTIs), protease inhibitors (PIs), and first-generation 
INSTI-based antiretroviral regimens (ARVs). It has the po-
tential to make big improvements in HIV control globally and 
within patients. This is perhaps the most “precious” HIV drug 
available. The integrase mutation R263K has been observed in 
tissue culture experiments and in patients treated with dolute-
gravir monotherapy in clinical trials. Globally, adherence and 
monitoring may be less than optimal and therefore DTG re-
sistance more common. This is particularly important in low–
middle-income countries, where patients may remain on failing 
regimens for longer periods of time and accumulate drug resist-
ance. Data on this mutation in non–subtype B infections do not 
exist. We describe the first report of the R263K integrase muta-
tion in a dolutegravir-exposed subtype D–infected individual 
with vertically acquired HIV. We have used deep sequencing of 
longitudinal samples to highlight the change in resistance over 
time while on a failing regimen. The case highlights that poorly 
adherent patients should not be offered dolutegravir even as 
part of a combination regimen and that protease inhibitors 
should be used preferentially.
Keywords. adolescents; ARVs; dolutegravir; HIV; 
resistance.
Dolutegravir (DTG), a second-generation integrase 
strand-transfer inhibitor (INSTI), is equivalent or supe-
rior to current non-nucleotide reverse transcriptase inhibi-
tors (NNRTIs), protease inhibitors (PIs), and first-generation 
INSTI-based antiretroviral regimens (ARVs) [1]. DTG has been 
shown to have excellent efficacy, tolerability, few drug–drug 
interactions, and has the potential to reduce pill burden.
DTG appears to have a high genetic barrier to resistance, 
unlike the other drugs within the INSTI class, raltegravir and 
elvitegravir, which select for major resistance mutations such as 
N155H, Y143H/R/C, G140A/S, and Q148H/R/K. DTG retains 
activity in the face of these mutations, although mutations at 
G140 and Q148 together can result in significant drug resist-
ance to DTG [2, 3].
Treatment-naïve patients taking combination ARV reg-
imens containing dolutegravir who experience virological 
failure are rarely found to have mutations in the integrase gene 
[4]. Dolutegravir monotherapy in naïve patients, on the other 
hand, is associated with more frequent selection of drug resist-
ance mutations such as R263K, G118R, S230 [2], and possibly 
resistance mutations outside the integrase gene [5, 6]. In treat-
ment-experienced patients, DTG resistance is also observed, 
most commonly in those previously treated with raltegravir 
[7, 8], although not exclusively [4]. A  number of additional 
mutations observed in patients can increase DTG resistance, 
including L74M and E138K [9, 10].
The integrase mutation R263K confers moderate resistance 
to DTG with a significant reduction of in vitro replication fit-
ness [11]. It has been observed in treatment-naïve patients by 
ultradeep sequencing, in experienced patients [4], and recently 
as transmitted drug resistance [12]. Most reports of the R263K 
mutation stem from subtype B–infected individuals in high-in-
come settings treated with ABC/3TC/DTG or DTG monother-
apy. In low–middle-income settings, R263K and other DTG 
resistance mutations may be more common where patients 
remain on failing regimens for longer periods of time and use 
alternate NRTIs temporarily due to stockouts or undisclosed 
ARV use, thereby accumulating multi-NRTI resistance [13–15].
We describe the first report of the R263K integrase mutation 
in a dolutegravir-exposed subtype D–infected individual with 
vertically acquired HIV.
CASE REPORT
A 22-year-old East African woman with vertically acquired 
HIV had been diagnosed shortly after birth. Her baseline viral 
load (VL) was 375  000 copies/mL, her CD4 was 150 cells/
mm3, and she had subtype D infection. At diagnosis, zidovu-
dine monotherapy was commenced. Didanosine was added 
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2  years later, and she was switched to stavudine, lamivudine, 
and nelfinavir at 3 years of age. The VL dropped to 700 copies/
mL; however, it rebounded to 6000 copies/mL: at that time, a 
first resistance test showed M184V and D30N mutations. The 
patient then received zalcitabine, abacavir, and amprenavir. 
Subsequently, she maintained poor virological control despite 
changing antiretrovirals three times, with NNRTIs introduced 
during these changes (Table 1). Poor adherence continued until 
11  years of age, when virological suppression was achieved 
with maraviroc, etravirine, and twice-daily darunavir/ritonavir. 
Subsequently, she disengaged from care, with inconsistent at-
tendance over a period of 8 years. On re-engagement in care, 
her VL was 1610 copies/mL, and her CD4 was 104 cells/mm3. 
At that time, resistance testing showed NRTI (M184V, T69D, 
T215S, D67N, K219Q), NNRTI (Y181C, Y188L, H221Y) and 
PI (L10I, D30N, K20T, L33F, K43T, N88D) resistance, with PI 
resistance to nelfinavir. Integrase polymorphisms (17N, 256E, 
112V, 113V, 201I, 234I) were detected. Maraviroc, etravirine, 
and darunavir/ritonavir (twice daily) were restarted. This reg-
imen was simplified to darunavir/ritonavir and maraviroc, 
and subsequently to darunavir/ritonavir monotherapy once 
virological suppression was achieved. Six months later, the VL 
rebounded to 8600 copies/mL, and DTG 50 mg once a day was 
added. Poor engagement continued for 18 months; at this later, 
time integrase resistance testing showed the R263K mutation 
conferring low-level resistance to DTG and raltegravir, with in-
termediate resistance to elvitegravir. R263K was confirmed by 
next-generation sequencing (NGS) using an analysis percentage 
minority variant threshold of >20%. To avoid accumulation of 
integrase resistance mutations with ongoing poor adherence, 
she was switched to tenofovir, darunavir/ritonavir. Follow-up 
NGS sequencing 3 months after the first resistance test showed 
the R263K mutation at <5% in a sample with a VL of 61 000 
copies/mL.
Reasons for poor adherence and disengagement over time in-
cluded drug adverse reactions and pill burden, a lack of family 
support, and lack of finances to attend outpatient appointments. 
The patient reported low mood, which reduced her motivation 
to take ARVs and engage in care. Despite multiple strategies 
to facilitate adherence, this patient declined psychological and 
mental health support.
DISCUSSION
The World Health Organization has recommended that 
countries consider a change from efavirenz-based regimens 
to dolutegravir-based regimens where pretreatment drug 
resistance to NNRTI has exceeded 15% [16, 17]. If DTG 
scale-up is to occur, drug resistance to DTG in different HIV 
subtypes needs to be monitored. Although at present signifi-
cant DTG resistance in sub-Saharan populations is very rare 
[18], it has been documented recently in a heavily experi-
enced patient who had previously failed raltegravir. We re-
port occurrence of the R263K integrase mutation 18 months 
into treatment with DTG in the context of vertically acquired 
subtype D infection. This mutation is known to reduce viral 
fitness, and its loss was associated with an increase in viral 
load [19]. Further surveillance for dolutegravir resistance is 
warranted globally.
Table 1. Summary of Antiretroviral History
Age, y Antirsetrovirals VL on Starting ARVs VL After Starting ARVs Resistance Test on Regimen
0 AZT 375 000 -
2 AZT, DDI - 375 000  
3 D4T, 3TC, NFV - 700 M184V, D30N
4 DDC, ABC, AMP 6000 -  
6 D4T, DDI, NVP - 31 000  
8 DDI, EFV, NVP 17 000 25 000  
10 TIP, TDF, FTC 34 000 <50  
18 MVC, ETV, DRV/RIT 1610  M184V, T69D, T215S, D67N, K219Q, Y181C, Y188L, H221Y, L10I, 
D30N, K20T, L33F, K43T, N88D
 MVC, DRV/RIT - <50  
 DRV/RIT <50   
19 DRV/RIT, DTG (OD) 8600  R263K INT 50.8%, L33F PR 99.7%, N88D PR 99.7%, D30N PR 
99.9%, K43T PR 98.8%, D67N RT 92.3%, T215S RT 99.6%, 
K219Q RT 99.7%, T69D RT 99.8%, Y181C RT 99.8%, Y188L RT 
99.8%, H221Y RT 99.7%
20 DRV/RIT, TDF 99 000  R263K INT 20.7%, K20T PR 99.7%, L33F PR 99.7%, N88D PR 
99.8%, D30N PR 99.8%, K43T PR 99.7%, D67N RT 90.1%, 
T215S RT 99.6%, K219Q RT 99.8%, T69D RT 98.2%, Y181C RT 
99.8%, Y188L RT 99.8%, H221Y RT 99.8%
% refers to abundance by ultradeep sequencing for the last 2 time points.
Abbreviations: 3TC, lamivudine; ABC, abacavir; AMP, amprenavir; AZT, zidovudine; D4T, stavudine; DDC, zalcitabine; DDI, didanosine; DRV/RIT, darunavir/ritonavir; EFV, efavirinez; ETV, etravir-
ine; FTC, emtricitabine; INT, intergrase; MVC, maraviroc; NFV, nelfinavir; NGS, next-generation sequencing; NVP, nevirapine; OD, once a day; PI, protease inhibitor; RT, reverse transcriptase; 
TDF, tenofovir; TIP, tipranavir. 
ID CASE • ofid • 3
Acknowledgments
Potential conflicts of interest. All Authors: No reported conflicts. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Kandel CE, Walmsley SL. Dolutegravir - a review of the pharmacology, efficacy, 
and safety in the treatment of HIV. Drug Des Devel Ther 2015; 9:3547–55.
2. Blanco JL, Marcelin AG, Katlama C, Martinez E. Dolutegravir resistance muta-
tions: lessons from monotherapy studies. Curr Opin Infect Dis 2018; 31:237–45.
3. Castagna A, Maggiolo F, Penco G, et al; VIKING-3 Study Group. Dolutegravir 
in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resis-
tant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 
210:354–62.
4. Lepik  KJ, Harrigan  PR, Yip  B, et  al. Emergent drug resistance with integrase 
strand transfer inhibitor-based regimens. AIDS 2017; 31:1425–34.
5. Wijting IEA, Lungu C, Rijnders BJA, et al. HIV-1 resistance dynamics in patients 
failing dolutegravir maintenance monotherapy. J Infect Dis 2018; 218(5):688–97.
6. Malet I, Subra F, Charpentier C, et al. Mutations located outside the integrase gene 
can confer resistance to HIV-1 integrase strand transfer inhibitors. MBio 2017; 
8:e00922-17.
7. Malet I, Ambrosio FA, Subra F, et al. Pathway involving the N155H mutation in 
HIV-1 integrase leads to dolutegravir resistance. J Antimicrob Chemother 2018; 
73:1158–66.
8. Fourati S, Charpentier C, Amiel C, et al; ANRS AC11 Resistance Study Group. 
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on ral-
tegravir: a French national study of raltegravir-experienced HIV-1-infected 
patients. J Antimicrob Chemother 2015; 70:1507–12.
9. Eron  JJ, Clotet  B, Durant  J, et  al; VIKING Study Group. Safety and efficacy 
of dolutegravir in treatment-experienced subjects with raltegravir-resistant 
HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 2013; 
207:740–8.
10. Naeger LK, Harrington P, Komatsu T, Deming D. Effect of dolutegravir functional 
monotherapy on HIV-1 virological response in integrase strand transfer inhibitor 
resistant patients. Antivir Ther 2016; 21:481–8.
11. Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation 
in HIV-1 integrase that confers low-level resistance to the second-generation inte-
grase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696–705.
12. Cochrane S, Daniel J, Forsyth S, Smit E. First reported case of integrase (R263K, 
G163R) and reverse transcriptase (M184V)-transmitted drug resistance from a 
drug-naive patient failing Triumeq. AIDS 2018; 32:1905–7.
13. Gupta  RK, Hill  A, Sawyer  AW, et  al. Virological monitoring and resistance to 
first-line highly active antiretroviral therapy in adults infected with HIV-1 treated 
under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 
2009; 9:409–17.
14. Goodall RL, Dunn DT, Nkurunziza P, et al; DART Virology Group. Rapid accu-
mulation of HIV-1 thymidine analogue mutations and phenotypic impact fol-
lowing prolonged viral failure on zidovudine-based first-line ART in sub-Saharan 
Africa. J Antimicrob Chemother 2017; 72:1450–5.
15. Gregson J, Kaleebu P, Marconi VC, et al. Occult HIV-1 drug resistance to thy-
midine analogues following failure of first-line tenofovir combined with a cyto-
sine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective 
multi-centre cohort study. Lancet Infect Dis 2017; 17:296–304.
16. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or 
re-initiation of first-line antiretroviral therapy in low-income and middle-income 
countries: a systematic review and meta-regression analysis. Lancet Infect Dis 
2018; 18:346–55.
17. WHO. Guidelines on the public health response to pretreatment HIV drug resist-
ance. 2017. http://who.int/hiv/pub/guidelines/hivdr-guidelines-2017/. Accessed 
28 July 2018.
18. Inzaule SC, Hamers RL, Noguera-Julian M, et al. Primary resistance to integrase 
strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in 
sub-Saharan Africa. J Antimicrob Chemother 2018; 73:1167–72.
19. Chaouchi N, Wallon C, Taieb J, et al. Interferon-alpha-mediated prevention of in 
vitro apoptosis of chronic lymphocytic leukemia B cells: role of bcl-2 and c-myc. 
Clin Immunol Immunopathol 1994; 73:197–204.
